Mahwah, New Jersey, February 12, 2025 – Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK), has announced the launch of Clindamycin Phosphate Foam, 1% in the U.S. market. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin® Foam, 1%, from Mylan Pharmaceuticals Inc.
Market Overview
According to IQVIA™ sales data for the 12-month period ending December 2024, the total Evoclin® Foam, 1% market recorded annual sales of approximately $5.8 million.About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. is a global research-led pharmaceutical company operating in branded, generics, and OTC segments. The company focuses on therapeutic areas including respiratory, dermatology, and oncology. With 11 world-class manufacturing facilities across four continents and operations in over 80 countries, Glenmark continues to strengthen its presence in the global pharmaceutical market.Notably, Glenmark was recognized in Scrip 100, ranking among the Top 100 biopharmaceutical companies in 2023. Additionally, the Generics Bulletin listed it among the Top 50 Generics and Biosimilar companies by sales in 2024. The company's Green House Gas (GHG) emission reduction targets were approved by the Science Based Target initiative (SBTi) in 2023, making Glenmark the second Indian pharmaceutical company to achieve this distinction.
Strategic Significance
The launch of Clindamycin Phosphate Foam, 1% aligns with Glenmark’s commitment to expanding its generic portfolio in the U.S. dermatology market. The product is expected to strengthen its positioning in the niche topical treatments segment.This strategic launch is expected to support Glenmark's growth trajectory in the U.S. generics market, enhancing its bioequivalent and cost-effective therapeutic solutions portfolio.